Joint Clinical Trials Office

A Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia

Clinical Trial Details

The purpose of this study is to evaluate the safety and effectiveness of BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia.
   
In this study BAL0891, tislelizumab and paclitaxel will be given intravenously (meaning through a needle in the vein directly into the blood). 
   
Total length of participation in this research will vary depending on disease status.

Key Eligibility: 
  1. Open to men and women above the age of 18 who have been diagnosed with Relapse/refractory (R/R) acute myeloid leukemia (AML).
  2. Participants must not have received ≥ 4 prior lines of cytotoxic chemotherapy-containing, anti-cancer treatment.

Detailed eligibility will be reviewed when contacting the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Devonie Manzano, RN
212-746-7117
dgm4004@med.cornell.edu

Primary Investigator(s)

Pinkal Desai, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

2507029055

ClinicalTrials.gov:

NCT05768932

Sponsor:

TTK-CS-101

Status

Open to Enrollment

Age Group

Adult

Sponsor

  • SillaJen, Inc

Disease

Leukemia
Acute Myeloid Leukemia